

EWG Program

Colorectal Cancer Screening Committee (CRC SC): EWG Sessions – **Berlin**

Friday, October 3, 2025 – 08:00 am – 12:00 pm (CEST)

NH Collection Berlin Mitte Friedrichstrasse
Friedrichstrasse 96, 10117 Berlin, Germany
Room: Madrid 1&2

Groups:

FIT for Screening
Inequities in CRC Screening
Polyp Detection, Characterization, Resection and AI
Surveillance after Colorectal Neoplasia
Evaluation of New Tests
PCCR & Quality in Colonoscopy

Goals of the meeting:

To provide updates on recent advances in CRC screening
To seek advice and comments on future initiatives
To reach consensus on controversial areas

Session 1 A: FIT for Screening

Chairs: Manon Spaander (the Netherlands) & Sally Benton (UK)

Time: 8:00 am – 9:10 am

08:00	Welcome by conveners	
08:05	The ability of a FIT pilot to predict positivity and uptake – the English experience	<i>Andres Tamm (UK)</i>
08:15	Discussion	
08:20	Impact of changing the FIT method	<i>Anja de Jong (the Netherlands)</i>
08:30	Discussion	
08:35	Impact of changing the FIT method	<i>Elyse Rijnders (the Netherlands)</i>
08:45	Discussion	
08:50	EVIDENCE project - The effect on mortality and incidence	<i>Johanes Blom (Sweden)</i>
09:00	Discussion	
09:05	Closing remarks	

Session 1 B: Inequities in CRC Screening

Chairs: Robert Kerrison (UK) & Yasemin Hirst (UK)

Time: 8:00 am – 9:10 am

08:00 am	Welcome & Introduction from the Chairs	
08:05 am	Inclusive cancer screening research: Challenges and strategies in reach and involvement of underserved groups	<i>Mirjam Fransen (the Netherlands)</i>
08:20 am	Introducing CRC Screening in Sub-Saharan Africa: Building Equity from the Ground Up	<i>Lucy Mwangi (the Netherlands)</i>
08:30 am	The role of creative visual arts-based approaches to promote uptake of, and reduce inequities in, bowel cancer screening	<i>Joanne Cairns (UK)</i>
08:40 am	Co-designing interventions to reduce health inequalities for bowel cancer screening for adults with severe mental illness	<i>Steven Robinson (UK)</i>
08:50 am	Discussion	
09:10 am	Meeting adjourns	

Session 2 A: Polyp Detection, Characterization, Resection and AI

Chairs: David Tate (Belgium) & Matt Rutter (UK)

Time: 9:15 am – 10:25 am

09:15 am	Welcome by conveners	
09:20 am	Hot vs Cold Snare for Colonic Adenomas: Revisiting the Evidence	<i>Andrea Sorge (Italy)</i>
09:35 am	Piecemeal Cold Resection of Serrated Lesions >10mm: Expert Method or Generalist Solution?	<i>David Tate (Belgium)</i>
09:50 am	Discussion	
10:25 am	Meeting adjourns	

Session 2 B: Surveillance after Colorectal Neoplasia

Chairs: Uri Ladabaum (USA) & Rodrigo Jover (Spain)

Time: 09:15 am – 10:25 am

09:15 am	Welcome by conveners	
09:20 am	Long-Term Colorectal Cancer Incidence After Serrated Polyp Removal: A Posthoc Assessment of COLONPREV Data	<i>Joaquín Cubiella (Spain)</i>
09:35 am	Future trends in post-polypectomy surveillance	<i>Rodrigo Jover (Spain)</i>
09:50 am	Discussion	
10:25 am	Meeting adjourns	

Coffee Break (25 minutes)

Session 3 A: Evaluation of New Tests

Chairs: Robert Bresalier (USA) & Carlo Senore (Italy)

Time: 10:50 am – 12:00 pm

10:50 am	Welcome by conveners	
10:55 am	Understanding the rapidly changing global landscape of CRC screening and the varying new test performance metrics: FDA label vs Pivotal Trial	<i>John B Kisiel (USA)</i>
11:07 am	Assessing cost-effectiveness of blood-based tests: do we have enough information?	<i>Robert E Schoen (USA)</i>
11:19 am	From Detection to Prevention - Early Evidence from RNA based Screening Test for Precancerous Lesions compared to different FIT cut-offs	<i>Lena Krammes (Germany)</i>
11:31 am	Discussion	
12:00 pm	Meeting adjourns	

Session 3 B: PCCR & Quality in Colonoscopy

Chairs: Nick Burr (UK) & Ulrike Haug (Germany)

Time: 10:50 am – 12:00 pm

10:50 am	Welcome by conveners	
10:55 am	PCCRC introduction: What's new since the last WEO meeting	<i>Nick Burr (UK)</i>
11:05 am	The 3-year PCCRC rate as per the WEO methodology: Systematic review and meta-analysis	<i>Rawen Kader (UK)</i>
11:20 am	Harm from PCCRC	<i>Nick Burr (UK)</i>
11:35 am	Points to discuss (interactive part) <ul style="list-style-type: none">• How to communicate the risk of PCCRC?• Is too much emphasis placed on the 3-year PCCRC rates (rather than longer intervals)?	<i>Ulrike Haug (Germany)</i>
11:50 am	Summary and next steps <ul style="list-style-type: none">• WEO methodology, update to guidance document?• How WEO can help services with PCCRC rates and route cause analysis?• Announcement of a WEO survey on PCCRC rates (from which countries are these available?)	<i>Nick Burr (UK)</i> <i>Ulrike Haug (Germany)</i>
12:00 pm	Meeting adjourns	

We would like to thank the following partners for their support:

WEO Principal sponsor:

OLYMPUS

Gold level sponsor:



EIKEN CHEMICAL

**Mast
Group**



Silver level sponsors:



Canon
CANON MEDICAL DIAGNOSTICS

**EXACT
SCIENCES**

FUJIFILM
Value from Innovation

SENTINEL
D I A G N O S T I C S